Global Hematological Cancers Market Analysis 2016 - Forecast to 2022

  • ID: 3845846
  • Report
  • Region: Global
  • 129 pages
  • Hoovers Research
1 of 3
This analysis is one of the most accurate studies performed using the combinational analytical tools. The report contains up to date financial data derived from varied research sources to present unique and reliable analysis. Assessment of major trends with potential impact on the market during the next five years, including a deep dive analysis of market segmentation which comprises of sub markets, regional and country level analysis. The report provides a comprehensive outlook about the market share along with strategic recommendations based on the emerging segments.

This report analyzes the global markets for "Hematological Cancers". The market assessment is performed through standard and the tailored research methodology approach. The market overview offers in depth analysis at the regional and country level, for instance North America (U.S., Canada and Mexico), Europe (Germany, France, Italy, U.K. and Spain), Asia-Pacific (China, Japan, India, Australia, South Korea and Rest of APAC) and Rest of the World (Middle East, Africa and Latin America). Annual estimations and forecasts are provided from the year 2013 to 2022 for each given segment and sub segments. Market data derived from the authenticated and reliable sources is subjected to validation from the industry experts. The report also analyzes the market by discussing market dynamics such as drivers, constraints, opportunities, threats, challenges and other market trends.

Competitive landscaping provides the recent activities performed by the active players in the market. Activities such as product launch, agreements, joint ventures, partnerships, acquisitions and mergers, and other activities.

This report provides:
- Market Sizing estimations and forecasts for a minimum of 6 years of all the given segments, sub segments and the regional markets
- Identifying market dynamics (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Regional and country level market analysis
- Competitive landscaping mapping the key common trends
- Company profiling covering the financials, recent activities and the future strategies
- Supply chain trends mapping the recent advancements
- Strategic recommendations for the new entrants
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1 Introduction
1.1 Scope of the Report
1.2 Report Description
1.3 Research Methodology
1.4 Research Sources
1.4.1 Secondary Research
1.4.2 Primary Research
1.4.3 Assumptions
1.5 List of Abbreviations

2 Executive Summary

3 Market Analysis
3.1 Market Segmentation
3.2 Market Size Estimation
3.3 Market Drivers
3.4 Market Constraints
3.5 Pipeline Analysis

4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Hematological Cancers Market by Blood Cancer Types
5.1 Introduction
5.2 Myeloma
5.2.1 Multiple Myeloma
5.2.2 Myelodysplastic Syndrome
5.3 Leukemia
5.3.1 Acute Myeloid Leukemia
5.3.2 Chronic Myeloid Leukemia
5.4 Lymphoma
5.4.1 Acute Lymphoma
5.4.2 Chronic Lymphoma
5.4.3 Hodgkin Lymphoma
5.4.4 Non Hodgkin Lymphoma
5.5 Malignant Immunoproliferative Cancer

6 Hematological Cancers Market by Treatment
6.1 Introduction
6.2 Pharmacological Therapies
6.3 Stem Cell Transplantation
6.4 Surgery and Radiation Therapy
6.4.1 Chemotherapy
6.4.2 Radiotherapy
6.4.3 Immunotherapy
6.5 Anemia Treatment
6.6 Thrombosis Treatment
6.7 Neutopenia Treatment
6.8 Symptomatic treatment

7 Hematological Cancers Market by Product
7.1 Introduction
7.2 Imbruvica (ibrutinib)
7.3 Kyprolis (carfilzomib)
7.4 Pomalyst (pomalidomide)
7.5 Sprycel (dasatinib)
7.6 Revlimid (lenalidomide)
7.7 Rituxan/Mabthera (rituximab)
7.8 Adcetris (brentuximab vedotin)
7.9 Vidaza (azacitidine)
7.10 Tasigna (nilotinib)
7.11 Velcade (bortezomib)
7.12 Gleevec/Glivec (Imatinib)

8 Hematological Cancers Market by Disease
8.1 Introduction
8.2 Epidemiology
8.3 Pathophysiology of Leukemic Stem Cells
8.4 Kidney Diseases
8.5 Genetic Diseases
8.6 Other Diseases

9 Hematological Cancers Market by End User
9.1 Introduction
9.2 Hospitals
9.3 Clinical laboratories
9.4 Academic and Research Institutes
9.5 Other End Users

10 Geographical Segmentation
10.1 North America
10.1.1 US
10.1.2 Canada
10.1.3 Mexico
10.2 Europe
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 UK
10.2.5 Spain
10.3 Asia Pacific
10.3.1 Japan
10.3.2 China
10.3.3 India
10.3.4 Australia
10.3.5 New Zealand
10.3.6 Rest of Asia Pacific
10.4 RoW
10.4.1 Latin America
10.4.2 Middle East
10.4.3 Africa
10.4.4 Others

11 Vendor Landscaping
11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.4 Expansions
11.5 Other Key Strategies

12 Company Profiles
12.1 Karyopharm Therapeutics
12.1.1 Business Overview
12.1.2 SWOT Analysis
12.1.3 Financial Overview
12.1.4 Strategy
12.1.5 Key Activities
12.2 Johnson & Johnson
12.3 Roche Diagnostics A/S
12.4 AbbVie
12.5 Novartis
12.6 Kite Pharma
12.7 Celgene Corporation
12.8 Abbott Laboratories
12.9 Beckman Coulter
12.10 HemoCue AB
12.11 C. R. Bard, Inc.
12.12 Siemens AG
12.13 Sysmex
12.14 Mindray Medical International Limited
12.15 Bio-Rad Laboratories, Inc.
12.16 The Medicine Company
12.17 Pharmacyclics
12.18 Horiba, Ltd
12.19 DiagnoCure Inc.
12.20 Astellas Pharma US, Inc.
13 Appendix
14 Disclaimer

List of Tables
Table 1 Global Hematological Cancers Market Analysis, by Region, 2013-2022 ($MN)
Table 2 Global Hematological Cancers Market Analysis, by Blood Cancer Types, 2013-2022 ($MN)
Table 3 Global Myeloma Market Analysis, by Region, 2013-2022 ($MN)
Table 4 Global Myeloma Market Analysis, by Treatment, 2013-2022 ($MN)
Table 5 Global Myeloma Market Analysis, by Product, 2013-2022 ($MN)
Table 6 Global Myeloma Market Analysis, by Disease, 2013-2022 ($MN)
Table 7 Global Myeloma Market Analysis, by End User, 2013-2022 ($MN)
Table 8 Global Leukemia Market Analysis, by Region, 2013-2022 ($MN)
Table 9 Global Leukemia Market Analysis, by Treatment, 2013-2022 ($MN)
Table 10 Global Leukemia Market Analysis, by Product, 2013-2022 ($MN)
Table 11 Global Leukemia Market Analysis, by Disease, 2013-2022 ($MN)
Table 12 Global Leukemia Market Analysis, by End User, 2013-2022 ($MN)
Table 13 Global Lymphoma Market Analysis, by Region, 2013-2022 ($MN)
Table 14 Global Lymphoma Market Analysis, by Treatment, 2013-2022 ($MN)
Table 15 Global Lymphoma Market Analysis, by Product, 2013-2022 ($MN)
Table 16 Global Lymphoma Market Analysis, by Disease, 2013-2022 ($MN)
Table 17 Global Lymphoma Market Analysis, by End User, 2013-2022 ($MN)
Table 18 Global Malignant Immunoprolifeative Cancer Market Analysis, by Region, 2013-2022 ($MN)
Table 19 Global Malignant Immunoprolifeative Cancer Market Analysis, by Treatment, 2013-2022 ($MN)
Table 20 Global Malignant Immunoprolifeative Cancer Market Analysis, by Product, 2013-2022 ($MN)
Table 21 Global Malignant Immunoprolifeative Cancer Market Analysis, by Disease, 2013-2022 ($MN)
Table 22 Global Malignant Immunoprolifeative Cancer Market Analysis, by End User, 2013-2022 ($MN)
Table 23 Global Hematological Cancers Market Analysis, by Treatment, 2013-2022 ($MN)
Table 24 Global Pharmacological Therapies Market Analysis, by Region, 2013-2022 ($MN)
Table 25 Global Pharmacological Therapies Market Analysis, by Blood Cancer Types, 2013-2022 ($MN)
Table 26 Global Pharmacological Therapies Market Analysis, by Product, 2013-2022 ($MN)
Table 27 Global Pharmacological Therapies Market Analysis, by Disease, 2013-2022 ($MN)
Table 28 Global Pharmacological Therapies Market Analysis, by End User, 2013-2022 ($MN)
Table 29 Global Stem Cell Transplantation Market Analysis, by Region, 2013-2022 ($MN)
Table 30 Global Stem Cell Transplantation Market Analysis, by Blood Cancer Types, 2013-2022 ($MN)
Table 31 Global Stem Cell Transplantation Market Analysis, by Product, 2013-2022 ($MN)
Table 32 Global Stem Cell Transplantation Market Analysis, by Disease, 2013-2022 ($MN)
Table 33 Global Stem Cell Transplantation Market Analysis, by End User, 2013-2022 ($MN)
Table 34 Global Surgery and Radiation Therapy Market Analysis, by Region, 2013-2022 ($MN)
Table 35 Global Surgery and Radiation Therapy Market Analysis, by Blood Cancer Types, 2013-2022 ($MN)
Table 36 Global Surgery and Radiation Therapy Market Analysis, by Product, 2013-2022 ($MN)
Table 37 Global Surgery and Radiation Therapy Market Analysis, by Disease, 2013-2022 ($MN)
Table 38 Global Surgery and Radiation Therapy Market Analysis, by End User, 2013-2022 ($MN)
Table 39 Global Anemia Blood Cancer Types Market Analysis, by Region, 2013-2022 ($MN)
Table 40 Global Anemia Blood Cancer Types Market Analysis, by Blood Cancer Types, 2013-2022 ($MN)
Table 41 Global Anemia Blood Cancer Types Market Analysis, by Product, 2013-2022 ($MN)
Table 42 Global Anemia Blood Cancer Types Market Analysis, by Disease, 2013-2022 ($MN)
Table 43 Global Anemia Blood Cancer Types Market Analysis, by End User, 2013-2022 ($MN)
Table 44 Global Thrombosis Blood Cancer Types Market Analysis, by Region, 2013-2022 ($MN)
Table 45 Global Thrombosis Blood Cancer Types Market Analysis, by Blood Cancer Types, 2013-2022 ($MN)
Table 46 Global Thrombosis Blood Cancer Types Market Analysis, by Product, 2013-2022 ($MN)
Table 47 Global Thrombosis Blood Cancer Types Market Analysis, by Disease, 2013-2022 ($MN)
Table 48 Global Thrombosis Blood Cancer Types Market Analysis, by End User, 2013-2022 ($MN)
Table 49 Global Neutopenia Blood Cancer Types Market Analysis, by Region, 2013-2022 ($MN)
Table 50 Global Neutopenia Blood Cancer Types Market Analysis, by Blood Cancer Types, 2013-2022 ($MN)
Table 51 Global Neutopenia Blood Cancer Types Market Analysis, by Product, 2013-2022 ($MN)
Table 52 Global Neutopenia Blood Cancer Types Market Analysis, by Disease, 2013-2022 ($MN)
Table 53 Global Neutopenia Blood Cancer Types Market Analysis, by End User, 2013-2022 ($MN)
Table 54 Global Symptomatic Blood Cancer Types Market Analysis, by Region, 2013-2022 ($MN)
Table 55 Global Symptomatic Blood Cancer Types Market Analysis, by Blood Cancer Types, 2013-2022 ($MN)
Table 56 Global Symptomatic Blood Cancer Types Market Analysis, by Product, 2013-2022 ($MN)
Table 57 Global Symptomatic Blood Cancer Types Market Analysis, by Disease, 2013-2022 ($MN)
Table 58 Global Symptomatic Blood Cancer Types Market Analysis, by End User, 2013-2022 ($MN)
Table 59 Global Hematological Cancers Market Analysis, by Product, 2013-2022 ($MN)
Table 60 Global Imbruvica (ibrutinib) Market Analysis, by Region, 2013-2022 ($MN)
Table 61 Global Imbruvica (ibrutinib) Market Analysis, by Blood Cancer Types, 2013-2022 ($MN)
Table 62 Global Imbruvica (ibrutinib) Market Analysis, by Treatment, 2013-2022 ($MN)
Table 63 Global Imbruvica (ibrutinib) Market Analysis, by Disease, 2013-2022 ($MN)
Table 64 Global Imbruvica (ibrutinib) Market Analysis, by End User, 2013-2022 ($MN)
Table 65 Global Kyprolis (carfilzomib) Market Analysis, by Region, 2013-2022 ($MN)
Table 66 Global Kyprolis (carfilzomib) Market Analysis, by Blood Cancer Types, 2013-2022 ($MN)
Table 67 Global Kyprolis (carfilzomib) Market Analysis, by Treatment, 2013-2022 ($MN)
Table 68 Global Kyprolis (carfilzomib) Market Analysis, by Disease, 2013-2022 ($MN)
Table 69 Global Kyprolis (carfilzomib) Market Analysis, by End User, 2013-2022 ($MN)
Table 70 Global Pomalyst (pomalidomide) Market Analysis, by Region, 2013-2022 ($MN)
Table 71 Global Pomalyst (pomalidomide) Market Analysis, by Blood Cancer Types, 2013-2022 ($MN)
Table 72 Global Pomalyst (pomalidomide) Market Analysis, by Treatment, 2013-2022 ($MN)
Table 73 Global Pomalyst (pomalidomide) Market Analysis, by Disease, 2013-2022 ($MN)
Table 74 Global Pomalyst (pomalidomide) Market Analysis, by End User, 2013-2022 ($MN)
Table 75 Global Sprycel (dasatinib) Market Analysis, by Region, 2013-2022 ($MN)
Table 76 Global Sprycel (dasatinib) Market Analysis, by Blood Cancer Types, 2013-2022 ($MN)
Table 77 Global Sprycel (dasatinib) Market Analysis, by Treatment, 2013-2022 ($MN)
Table 78 Global Sprycel (dasatinib) Market Analysis, by Disease, 2013-2022 ($MN)
Table 79 Global Sprycel (dasatinib) Market Analysis, by End User, 2013-2022 ($MN)
Table 80 Global Revlimid (lenalidomide) Market Analysis, by Region, 2013-2022 ($MN)
Table 81 Global Revlimid (lenalidomide) Market Analysis, by Blood Cancer Types, 2013-2022 ($MN)
Table 82 Global Revlimid (lenalidomide) Market Analysis, by Treatment, 2013-2022 ($MN)
Table 83 Global Revlimid (lenalidomide) Market Analysis, by Disease, 2013-2022 ($MN)
Table 84 Global Revlimid (lenalidomide) Market Analysis, by End User, 2013-2022 ($MN)
Table 85 Global Rituxan/Mabthera (rituximab) Market Analysis, by Region, 2013-2022 ($MN)
Table 86 Global Rituxan/Mabthera (rituximab) Market Analysis, by Blood Cancer Types, 2013-2022 ($MN)
Table 87 Global Rituxan/Mabthera (rituximab) Market Analysis, by Treatment, 2013-2022 ($MN)
Table 88 Global Rituxan/Mabthera (rituximab) Market Analysis, by Disease, 2013-2022 ($MN)
Table 89 Global Rituxan/Mabthera (rituximab) Market Analysis, by End User, 2013-2022 ($MN)
Table 90 Global Adcetris (brentuximab vedotin) Market Analysis, by Region, 2013-2022 ($MN)
Table 91 Global Adcetris (brentuximab vedotin) Market Analysis, by Blood Cancer Types, 2013-2022 ($MN)
Table 92 Global Adcetris (brentuximab vedotin) Market Analysis, by Treatment, 2013-2022 ($MN)
Table 93 Global Adcetris (brentuximab vedotin) Market Analysis, by Disease, 2013-2022 ($MN)
Table 94 Global Adcetris (brentuximab vedotin) Market Analysis, by End User, 2013-2022 ($MN)
Table 95 Global Vidaza (azacitidine) Market Analysis, by Region, 2013-2022 ($MN)
Table 96 Global Vidaza (azacitidine) Market Analysis, by Blood Cancer Types, 2013-2022 ($MN)
Table 97 Global Vidaza (azacitidine) Market Analysis, by Treatment, 2013-2022 ($MN)
Table 98 Global Vidaza (azacitidine) Market Analysis, by Disease, 2013-2022 ($MN)
Table 99 Global Vidaza (azacitidine) Market Analysis, by End User, 2013-2022 ($MN)
Table 100 Global Tasigna (nilotinib) Market Analysis, by Region, 2013-2022 ($MN)
Table 101 Global Tasigna (nilotinib) Market Analysis, by Blood Cancer Types, 2013-2022 ($MN)
Table 102 Global Tasigna (nilotinib) Market Analysis, by Treatment, 2013-2022 ($MN)
Table 103 Global Tasigna (nilotinib) Market Analysis, by Disease, 2013-2022 ($MN)
Table 104 Global Tasigna (nilotinib) Market Analysis, by End User, 2013-2022 ($MN)
Table 105 Global Velcade (bortezomib) Market Analysis, by Region, 2013-2022 ($MN)
Table 106 Global Velcade (bortezomib) Market Analysis, by Blood Cancer Types, 2013-2022 ($MN)
Table 107 Global Velcade (bortezomib) Market Analysis, by Treatment, 2013-2022 ($MN)
Table 108 Global Velcade (bortezomib) Market Analysis, by Disease, 2013-2022 ($MN)
Table 109 Global Velcade (bortezomib) Market Analysis, by End User, 2013-2022 ($MN)
Table 110 Global Gleevec/Glivec (Imatinib) Market Analysis, by Region, 2013-2022 ($MN)
Table 111 Global Gleevec/Glivec (Imatinib) Market Analysis, by Blood Cancer Types, 2013-2022 ($MN)
Table 112 Global Gleevec/Glivec (Imatinib) Market Analysis, by Treatment, 2013-2022 ($MN)
Table 113 Global Gleevec/Glivec (Imatinib) Market Analysis, by Disease, 2013-2022 ($MN)
Table 114 Global Gleevec/Glivec (Imatinib) Market Analysis, by End User, 2013-2022 ($MN)
Table 115 Global Hematological Cancers Market Analysis, by Disease, 2013-2022 ($MN)
Table 116 Global Epidemiology Market Analysis, by Region, 2013-2022 ($MN)
Table 117 Global Epidemiology Market Analysis, by Blood Cancer Types, 2013-2022 ($MN)
Table 118 Global Epidemiology Market Analysis, by Treatment, 2013-2022 ($MN)
Table 119 Global Epidemiology Market Analysis, by Product, 2013-2022 ($MN)
Table 120 Global Epidemiology Market Analysis, by End User, 2013-2022 ($MN)
Table 121 Global Pathophysiology of Leukemic Stem Cells Market Analysis, by Region, 2013-2022 ($MN)
Table 122 Global Pathophysiology of Leukemic Stem Cells Market Analysis, by Blood Cancer Types, 2013-2022 ($MN)
Table 123 Global Pathophysiology of Leukemic Stem Cells Market Analysis, by Treatment, 2013-2022 ($MN)
Table 124 Global Pathophysiology of Leukemic Stem Cells Market Analysis, by Product, 2013-2022 ($MN)
Table 125 Global Pathophysiology of Leukemic Stem Cells Market Analysis, by End User, 2013-2022 ($MN)
Table 126 Global Kidney Diseases Market Analysis, by Region, 2013-2022 ($MN)
Table 127 Global Kidney Diseases Market Analysis, by Blood Cancer Types, 2013-2022 ($MN)
Table 128 Global Kidney Diseases Market Analysis, by Treatment, 2013-2022 ($MN)
Table 129 Global Kidney Diseases Market Analysis, by Product, 2013-2022 ($MN)
Table 130 Global Kidney Diseases Market Analysis, by End User, 2013-2022 ($MN)
Table 131 Global Genetic Diseases Market Analysis, by Region, 2013-2022 ($MN)
Table 132 Global Genetic Diseases Market Analysis, by Blood Cancer Types, 2013-2022 ($MN)
Table 133 Global Genetic Diseases Market Analysis, by Treatment, 2013-2022 ($MN)
Table 134 Global Genetic Diseases Market Analysis, by Product, 2013-2022 ($MN)
Table 135 Global Genetic Diseases Market Analysis, by End User, 2013-2022 ($MN)
Table 136 Global Other Diseases Market Analysis, by Region, 2013-2022 ($MN)
Table 137 Global Other Diseases Market Analysis, by Blood Cancer Types, 2013-2022 ($MN)
Table 138 Global Other Diseases Market Analysis, by Treatment, 2013-2022 ($MN)
Table 139 Global Other Diseases Market Analysis, by Product, 2013-2022 ($MN)
Table 140 Global Other Diseases Market Analysis, by End User, 2013-2022 ($MN)
Table 141 Global Hospitals Market Analysis, by Region, 2013-2022 ($MN)
Table 142 Global Hospitals Market Analysis, by Blood Cancer Types, 2013-2022 ($MN)
Table 143 Global Hospitals Market Analysis, by Treatment, 2013-2022 ($MN)
Table 144 Global Hospitals Market Analysis, by Product, 2013-2022 ($MN)
Table 145 Global Hospitals Market Analysis, by Disease, 2013-2022 ($MN)
Table 146 Global Clinical laboratories Market Analysis, by Region, 2013-2022 ($MN)
Table 147 Global Clinical laboratories Market Analysis, by Blood Cancer Types, 2013-2022 ($MN)
Table 148 Global Clinical laboratories Market Analysis, by Treatment, 2013-2022 ($MN)
Table 149 Global Clinical laboratories Market Analysis, by Product, 2013-2022 ($MN)
Table 150 Global Clinical laboratories Market Analysis, by Disease, 2013-2022 ($MN)
Table 151 Global Academic and Research Institutes Market Analysis, by Region, 2013-2022 ($MN)
Table 152 Global Academic and Research Institutes Market Analysis, by Blood Cancer Types, 2013-2022 ($MN)
Table 153 Global Academic and Research Institutes Market Analysis, by Treatment, 2013-2022 ($MN)
Table 154 Global Academic and Research Institutes Market Analysis, by Product, 2013-2022 ($MN)
Table 155 Global Academic and Research Institutes Market Analysis, by Disease, 2013-2022 ($MN)
Table 156 Global Other End Users Market Analysis, by Region, 2013-2022 ($MN)
Table 157 Global Other End Users Market Analysis, by Blood Cancer Types, 2013-2022 ($MN)
Table 158 Global Other End Users Market Analysis, by Treatment, 2013-2022 ($MN)
Table 159 Global Other End Users Market Analysis, by Product, 2013-2022 ($MN)
Table 160 Global Other End Users Market Analysis, by Disease, 2013-2022 ($MN)
Note: Regional tables are presented in the similar manner as the above
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll